Oxford Biomedica PLC Result of AGM (1528N)

TIDMOXB

RNS Number : 1528N

Oxford Biomedica PLC

27 May 2022

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 27 May 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company") , a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 27 May 2022 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com

Copies of the document setting out the above resolutions passed at the 2022 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

On the Record Date (25 May 2022) there were 96,063,479 ordinary shares of 50 pence each in issue, each carrying one vote per share.

 
                                                      Votes 
                                     Votes              at 
                               For (incl. votes       other                                    Total 
            Resolution         at the Chairman's      proxy         Votes         Votes        votes 
                                  discretion)       Discretion     Against      Withheld*       cast     Result 
 
                 Ordinary resolutions 
     -------------------------------------------  ------------  -----------  ------------  -----------  ------- 
 
      To receive 
       the Company's 
       Accounts, 
       the Reports 
       of the Directors 
       and Auditor 
       and the 
       Strategic 
       Report for 
       the year 
       ended 31 
       December 
       2021.                     71,533,247             0          3,804                                 Passed 
 1                                 (99.99%)                        (0.01%)      907,786     71,537,051 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To receive 
       the Directors' 
       Remuneration 
       Report and 
       the Report 
       of the Auditor 
       on the Remuneration 
       Report for 
       the year 
       ended 31 
       December 
       2021.                     57,808,878             0        13,801,220                              Passed 
 2                                 (80.73%)                       (19.27%)      834,739     71,610,098 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To appoint 
       Dr. Michael 
       Hayden as 
       a Director.               62,539,719             0        9,295,954                               Passed 
 3                                 (87.06%)                       (12.94%)      609,164     71,835,673 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To appoint 
       Catherine 
       Moukheibir 
       as a Director.            71,748,494             0          86,921                                Passed 
 4                                 (99.88%)                        (0.12%)      609,422     71,835,415 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To appoint 
       Namrata 
       P. Patel 
       as a Director.            71,746,512             0          88,903                                Passed 
 5                                 (99.88%)                        (0.12%)      609,422     71,835,415 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       Dr. Roch 
       Doliveux 
       as a Director.            68,788,280             0        2,264,491                               Passed 
 6                                 (96.81%)                        (3.19%)     1,392,066    71,052,771 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       Professor 
       Dame Kay 
       Davies as 
       a Director.               69,259,453             0        2,575,962                               Passed 
 7                                 (96.41%)                        (3.59%)      609,422     71,835,415 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       Dr. Siyamak 
       Rasty as 
       a Director.               71,719,604             0         116,069                                Passed 
 8                                 (99.84%)                        (0.16%)      609,164     71,835,673 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       Stuart Paynter 
       as a Director.            71,206,012             0         629,661                                Passed 
 9                                 (99.12%)                        (0.88%)      609,164     71,835,673 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       Stuart Henderson 
       as a Director.            67,003,486             0        4,832,187                               Passed 
 10                                (93.27%)                        (6.73%)      609,164     71,835,673 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       Dr. Heather 
       Preston 
       as a Director             64,708,975             0        7,126,698 
 11                                (90.08%)                        (9.92%)      609,164     71,835,673   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       Robert Ghenchev 
       as a Director.            71,526,110             0         309,305 
 12                                (99.57%)                        (0.43%)      609,422     71,835,415   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To reappoint 
       KMPG LLP 
       as auditor.               71,831,890                        7,494 
 13                                (99.99%)             0          (0.01%)      605,453     71,839,384   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To authorise 
       the Directors 
       to agree 
       the remuneration 
       of the auditor.           71,832,849                        6,921 
 14                                (99.99%)             0          (0.01%)      605,067     71,839,770   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To authorise 
       the Directors 
       to allot 
       shares.                   67,355,882                      4,471,767 
 15                                (93.77%)             0          (6.23%)      617,188     71,827,649   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
                  Special resolutions 
     -------------------------------------------  ------------  -----------  ------------  -----------  ------- 
 
      To authorise 
       the Directors 
       to disapply 
       pre-emption 
       rights.                   70,888,310             0         937,061 
 16                                (98.70%)                        (1.30%)      619,466     71,825,371   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To authorise 
       the Directors 
       to further 
       disapply 
       pre-emption 
       rights for 
       acquisitions 
       and specified 
       capital 
       investments.              70,922,796             0         903,407 
 17                                (98.74%)                        (1.26%)      618,634     71,826,203   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 
      To permit 
       the Directors 
       to convene 
       general 
       meetings 
       (other than 
       annual general 
       meetings) 
       on not less 
       than 14 
       days' notice.             69,350,429             0        2,489,321      605,087 
 18                                (96.53%)                        (3.47%)                  71,839,750   Passed 
     ---------------------  --------------------  ------------  -----------  ------------  -----------  ------- 
 

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

In addition, further to the announcements by the Company in January and April, John Dawson has stepped down from the Company's Board of Directors after more than thirteen years of service with effect from the conclusion of today's AGM.

-Ends-

 
 Enquiries: 
 
  Oxford Biomedica plc: T: [phone] / E: [e-mail] 
 Stuart Paynter, Chief Financial Officer 
  Sophia Bolhassan, Head of Investor Relations 
 Consilium Strategic Communications: 
  T: [phone] / E: [e-mail] 
 
  Mary-Jane Elliott / Matthew Neal / Matthew Cole 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector(R) platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSEUFMWEESEII

(END) Dow Jones Newswires

May 27, 2022 13:03 ET (17:03 GMT)